Systematic review/meta-analysis on efficacy of allogeneic HCT in sickle cell disease: an international effort on behalf of the Pediatric Diseases Working Party of EBMT and the Sickle Cell Transplantation International Consortium

Sickle cell disease (SCD) is the most common inherited hemoglobinopathy affecting nearly 100,000 individuals in the United States and approximately 300,000 worldwide, with low-income countries bearing the highest burden.1, 2 It is associated with several complications including debilitating morbidity, organ injury, and shortened life expectancy. Progress have been made in recent years to the overall management of SCD, namely improved health maintenance surveillance programs, penicillin prophylaxis, chronic blood transfusions, vaccines, primary and secondary stroke prophylaxis, use of hydroxyurea and approval of novel agents such as L-glutamine, crizanlizumab, voxelotor, among others.

Source: Biology of Blood and Marrow Transplantation - December 10, 2020 Category: Hematology Authors: Madiha Iqbal, Tea Reljic, Selim Corbacioglu, Josu de la Fuente, Eliane Gluckman, Ambuj Kumar, Farah Yassine, Ernesto Ayala, Areej El-Jawahri, Hemant Murthy, Fahad Almohareb, Shahrukh K. Hashmi, Barbara Cappelli, Ali Alahmari, Graziana Maria Scigliuolo, Ad Source Type: research